Zolpidem hemitartarate

Drug Profile

Zolpidem hemitartarate

Alternative Names: Zolpidem hemitartarate orodispersible

Latest Information Update: 21 Jul 2016

Price : $50

At a glance

  • Originator Biolab Sanus Farmaceutica
  • Class Acetamides; Hypnosedatives; Pyridines; Sleep disorder therapies; Small molecules
  • Mechanism of Action GABA A receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Sleep disorders

Most Recent Events

  • 04 Jul 2016 Biolab Sanus Farmaceutica plans a phase I trial for Sleep disorders in Brazil (NCT02814058)
  • 23 Jun 2016 Preclinical trials in Sleep disorders in Brazil (PO) before June 2016 (NCT02814058)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top